TREATMENT OF DISEASES BY EPIGENETIC REGULATION

1 . A method for inhibiting BET proteins comprising administering a therapeutically effective amount of at least one compound of Formula I:

or stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein:

Q and V are independently selected from CH and nitrogen;

Ra 1 and Ra 3 are independently selected from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halogen, amino, amide, hydroxyl, heterocycle, and C 3 -C 6 cycloalkyl;

Rb 2 and Rb 6 are independently selected from hydrogen;

Rb 3 and Rb 5 are independently selected from hydrogen, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, hydroxyl, and amino;

or wherein Rb 2 and Rb 3 and/or Rb 5 and Rb 6 are optionally connected to form a cycloalkyl or a heterocycle;

represents a 3-8 membered ring system wherein:

W is selected from carbon and nitrogen;

Z is selected from CR 6 R 7 , NR 8 , oxygen, sulfur, —S(O)—, and —SO 2 —;

said ring system being optionally fused to another ring selected from cycloalkyl, heterocycle, and phenyl, and wherein said ring system is optionally selected from rings having the structures:

R 3 , R 4 , and R 5 are independently selected from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkenyl, C 1 -C 6 alkynyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, aryl, aryloxy, hydroxyl, amino, amide, oxo, —CN, and sulfonamide;

R 6 and R 7 are independently selected from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkenyl, C 1 -C 6 alkynyl, C 3 -C 6 cycloalkyl, aryl, halogen, hydroxyl, —CN, amino, and amido; and

R 8 is selected from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkenyl, C 1 -C 6 alkynyl, acyl, and C 3 -C 6 cycloalkyl; and

R 9 , R 10 , R 11 , and R 12 are independently selected from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkenyl, C 1 -C 6 alkynyl, C 3 -C 6 cycloalkyl, aryl, heterocycle, hydroxyl, sulfonyl, and acyl;

provided that:

if Q is CH, then at least one of Ra 1 and Ra 3 is not hydrogen;

if Z is NAc, then Ra 1 and Ra 3 are not hydrogen, and Ra 1 is not —OCH 2 CH 2 OMe; and

if Ra 1 and Ra 3 are both OMe, then R 8 is not —C(O)CH 2 OH.

2 . The method according to claim 1 , wherein:

Ra 1 is selected from methyl, ethyl, methoxy, ethoxy, and propoxy; and

R 3 and R 4 are independently selected from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkenyl, C 1 -C 6 alkynyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, aryloxy, aryl, hydroxyl, amino, amide, oxo, —CN, and sulfonamide; and

R 8 is selected from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkenyl, acyl, and C 1 -C 6 alkynyl.

3 . The method according to claim 1 , wherein:

Ra 1 is selected from methyl, ethyl, methoxy, ethoxy, and propoxy; and

R 3 and R 4 are independently selected from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkenyl, C 1 -C 6 alkynyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, aryloxy, aryl, hydroxyl, amino, amide, oxo, —CN, and sulfonamide; and

R 9 and R 10 are independently selected from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkenyl, C 1 -C 6 alkynyl, C 3 -C 6 cycloalkyl, aryl, heterocycle, sulfonyl, carbamate, carboxamide, and acyl.

4 . The method according to claim 1 , wherein:

Ra 1 is selected from methyl, ethyl, methoxy, ethoxy, and propoxy;

R 3 and R 4 are independently selected from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkenyl, C 1 -C 6 alkynyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, aryloxy, aryl, hydroxyl, amino, amido, oxo, —CN, and sulfonamide; and

R 8 is selected from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkenyl, C 1 -C 6 alkynyl, acyl, and C 3 -C 6 cycloalkyl.

5 . The method according to claim 1 , wherein:

Ra 1 is selected from methyl, ethyl, methoxy, ethoxy, and propoxy

Ra 3 is selected from C 1 -C 6 alkoxy, hydrogen, and halogen;

Rb 2 , Rb 3 , Rb 5 , and Rb 6 are each hydrogen;

is selected from

R 3 and R 4 are independently selected from hydrogen and C 1 -C 6 alkyl;

R 8 is selected from C 1 -C 6 alkyl and hydrogen; and

R 9 , R 10 , R 11 , and R 12 are independently selected from C 1 -C 6 alkyl, hydrogen, acyl, and sulfonyl.

6 . The method according to claim 1 , wherein:

Ra 1 is selected from methyl, ethyl, methoxy, ethoxy, and propoxy;

Ra 3 is selected from methoxy, hydrogen, and halogen;

Rb 3 and Rb 5 are each hydrogen;

is selected from

R 3 and R 4 are independently selected from hydrogen and methyl;

R 8 is selected from hydrogen, hydroxyethyl, butyl, acetyl, isopropyl, 4-hexanoyl, 4-isobutyryl, benzoyl, 4-fluorobenzoyl, 4-picolinoyl, 4-nicotinoyl, 4-isonicotinoyl, thiophene-2-carbonyl, 5-chloro-1-methyl-1H-pyrazole-4-carbonyl, 3,3,3-trifluoropropanoyl, 2,5-dichlorothiopene-3-carbonyl, cyclopropanecarbonyl, 4-fluorobenzyl, benzyl, 2,2,2-trifluoroethyl, tertbutoxycarbonyl, and formyl;

R 9 and R 10 are independently selected from hydrogen, methyl, cyclopropylmethyl, and acetyl; and

R 11 and R 12 are independently selected from hydrogen, acetyl, methanesulfonyl, dimethylaminocarbonyl, benzoyl, benzyl, ethyl, and isopropyl.

7 . The method according to claim 1 , wherein the compound of Formula I is selected from:

5,7-dimethoxy-2-(4-morpholinophenyl)quinazolin-4(3H)-one;

2-(4-((3R,5S)-4-acetyl-3,5-dimethylpiperazin-1-yl)phenyl)-5,7-dimethoxypyrido[2,3-d]pyrimidin-4(3H)-one;

2-(4-(4-hydroxypiperidin-1-yl)phenyl)-5,7-dimethoxypyrido[2,3-d]pyrimidin-4(3H)-one;

2-(4-((3R,5S)-4-acetyl-3,5-dimethylpiperazin-1-yl)phenyl)-5-methoxy-7-(2-methoxyethoxy)quinazolin-4(3H)-one;

2-(4-(4-isopropylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(4-acetylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(piperazin-1-yl)phenyl)quinazolin-4(3H)-one;

N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)acetamide;

N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)methanesulfonamide;

3-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)-1,1-dimethylurea;

2-(4-(4-hexanoylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(4-isobutyrylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(4-benzoylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(4-(4-fluorobenzoyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)benzamide;

5,7-dimethoxy-2-(4-(4-picolinoylpiperazin-1-yl)phenyl)quinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(4-nicotinoylpiperazin-1-yl)phenyl)quinazolin-4(3H)-one;

2-(4-(4-isonicotinoylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(4-(thiophene-2-carbonyl)piperazin-1-yl)phenyl)quinazolin-4(3H)-one;

2-(4-(4-(5-chloro-1-methyl-1H-pyrazole-4-carbonyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(4-(3,3,3-trifluoropropanoyl)piperazin-1-yl)phenyl)quinazolin-4(3H)-one;

2-(4-(4-(2,5-dichlorothiophene-3-carbonyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(4-(cyclopropanecarbonyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(4-(4-fluorobenzyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(4-benzylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)phenyl)quinazolin-4(3H)-one;

2-(4-(4-butylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(4-acetyl-1,4-diazepan-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(1,4-diazepan-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(4-methyl-1,4-diazepan-1-yl)phenyl)quinazolin-4(3H)-one;

N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)-N-ethylacetamide;

2-(4-((3R,5S)-4-acetyl-3,5-dimethylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-((3R,5S)-3,5-dimethylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(4-acetyl-3-methylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)pyrrolidin-3-yl)acetamide;

2-(4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidin-4-yl)-N-isopropylacetamide;

5-chloro-2-(4-(4-isopropylpiperazin-1-yl)phenyl)quinazolin-4(3H)-one;

2-(4-((3R,5S)-4-isopropyl-3,5-dimethylpiperazin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(piperidin-4-yl)phenyl)quinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(3-(methylamino)pyrrolidin-1-yl)phenyl)quinazolin-4(3H)-one;

tert-butyl 4-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperidine-1-carboxylate;

N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)pyrrolidin-3-yl)-N-methylacetamide;

2-(4-(4-(isopropylamino)piperidin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(1-acetylpiperidin-4-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(3-methylpiperazin-1-yl)phenyl)quinazolin-4(3H)-one;

N-benzyl-N-(1-(5-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)pyridin-2-yl)piperidin-4-yl)acetamide;

2-(6-(4-(benzylamino)piperidin-1-yl)pyridin-3-yl)-5,7-dimethoxyquinazolin-4(3H)-one;

4-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)piperazine-1-carbaldehyde;

2-(4-(3-(cyclopropylmethylamino)pyrrolidin-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(4-oxopiperidin-1-yl)phenyl)pyrido[2,3-d]pyrimidin-4(3H)-one;

and stereoisomers, tautomers, pharmaceutically acceptable salts, and hydrates thereof.

8 . A method of inhibiting BET proteins comprising administering a therapeutically effective amount of at least one compound of Formula II:

or stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein:

Q and V are independently selected from CH and nitrogen;

Ra 1 and Ra 3 are independently selected from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, halogen, amino, amide, hydroxyl, cycloalkyl, and heterocycle;

Rb 3 and Rb 5 are independently selected from hydrogen, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, hydroxyl, and amino;

Rn 1 is selected from hydrogen, C 1 -C 6 alkyl, and C 3 -C 6 cycloalkyl;

Rn 2 is selected from C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, heterocycle, aryl, alkenyl, sulfonyl and acyl;

or wherein Rn 1 and/or Rn 2 are optionally connected with Rb 3 and/or Rb 5 to form a 5- or 6-membered heterocyclic ring;

provided that:

at least one of Ra 1 and Ra 3 are not hydrogen; and

Rn 1 and Rn 2 are not both methyl or ethyl.

9 . The method according to claim 8 , wherein:

Q is CH;

V is nitrogen;

Ra 1 and Ra 3 are each C 1 -C 6 alkoxy;

Rb 3 is hydrogen;

Rn 1 is hydrogen;

Rn 2 is selected from sulfonyl, heterocycle, and aryl; and

Rb 5 is hydrogen or is connected with Rn 2 to form a heterocycle.

10 . The method according to claim 8 , wherein:

Q is CH;

V is nitrogen;

Ra 1 and Ra 3 are each methoxy;

Rb 3 is hydrogen;

Rn 1 is hydrogen;

Rn 2 is selected from methanesulfonyl, pyridin-4-yl, 4-methylphenyl, and pyridin-3-yl; and

Rb 5 is hydrogen or is connected with Rn 2 to form a heterocycle selected from (2-hydroxymethyl)-1H-pyrrol-5-yl, (2-hydroxyethyl)-1H-pyrrol-5-yl, 2-(pyrrolidin-1-yl-ylmethyl)-1H-pyrrol-5-yl, 3-(hydroxymethyl)-1H-pyrazol-5-yl, 2-(pyrrolidin-1-yl-ylethyl)-1H-pyrrol-5-yl, and 2-((dimethylamino)methyl)-1H-pyrrol-5-yl.

11 . The method according to claim 8 , wherein the compound of Formula II is selected from:

2-(4-(dimethylamino)naphthalen-1-yl)-6,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(bis(2-hydroxyethyl)amino)phenyl)-5,7-dimethoxypyrido[2,3-d]pyrimidin-4(3H)-one;

2-(2-(hydroxymethyl)-1H-indol-5-yl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(2-(2-hydroxyethyl)-1H-indol-5-yl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(2-(pyrrolidin-1-ylmethyl)-1H-indol-5-yl)quinazolin-4(3H)-one;

2-(3-(hydroxymethyl)-1H-indazol-5-yl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(2-(2-(pyrrolidin-1-yl)ethyl)-1H-indol-5-yl)quinazolin-4(3H)-one;

2-(2-((dimethylamino)methyl)-1H-indol-5-yl)-5,7-dimethoxyquinazolin-4(3H)-one;

N-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)methanesulfonamide;

5,7-dimethoxy-2-(4-(pyridin-4-ylamino)phenyl)quinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(p-tolylamino)phenyl)quinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(pyridin-3-ylamino)phenyl)quinazolin-4(3H)-one;

and stereoisomers, tautomers, pharmaceutically acceptable salts, and hydrates thereof.

12 . A method of inhibiting BET proteins in a subject, comprising administering a therapeutically effective amount of at least one compound of Formula III:

or stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein:

Q is selected from CH and nitrogen;

V is selected from CH and nitrogen;

X is selected from oxygen, sulfur, SR 1 , nitrogen, NR 6 R 7 , and CR 6 R 7 ;

Z is selected from unsubstituted C 1 -C 6 alkyl and C 1 -C 6 alkyl substituted with one or more groups selected from C 1 -C 3 alkyl, C 1 -C 3 alkoxy, cyclopropyl, hydroxyl, amino, and halogen;

n is selected from 0, 1, 2, or 3;

G is selected from heterocycle, cycloalkyl, and aryl;

R 1 is selected from hydrogen, and C 1 -C 6 alkyl;

R 6 and R 7 are independently selected from hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, heterocycle, C 1 -C 6 alkoxy, and halogen;

Ra 1 and Ra 3 are independently selected from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, halogen, amino, amide, hydroxyl, and heterocycle; and

Rb 3 and Rb 5 are independently selected from hydrogen, halogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 alkoxy, hydroxyl, and amino;

provided that:

if Ra 1 and Ra 3 are OMe, and Q is CH, then

at least one of Ra 1 and Ra 3 is not hydrogen; and

if Ra 3 is chloro, then Ra 1 is not hydrogen.

13 . The method according to claim 12 , wherein:

Q is selected from CH and nitrogen;

V is nitrogen;

Z is selected from unsubstituted C 1 -C 6 alkyl;

Ra1 is selected from methyl, ethyl, methoxy, ethoxy, and propoxy;

Ra 3 is selected from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halogen, and heterocycle;

Rb 3 and Rb 5 are independently selected from hydrogen and C 1 -C 6 alkyl;

X is selected from oxygen and CH 2 ;

n is selected from 0, 1, 2, or 3; and

G is selected from heterocycle, cycloalkyl, and aryl.

14 . The method according to claim 12 , wherein:

Q is selected from CH and nitrogen;

V is nitrogen;

Ra 1 is selected from methyl, ethyl, methoxy, ethoxy, and propoxy;

Ra 3 is selected from hydrogen, methyl, chlorine, fluorine, methoxy, isopropoxy, and pyrrolidin-1-yl;

Rb 3 and Rb 5 are independently selected from hydrogen and methyl; and

is selected from (N,N-dimethylpiperidine-1-carboxamide)-4-oxy, 1-acetylpiperidin-4-yloxy, 2-(isoindolin-2-yl)ethoxy, 2-(pyrrolidin-1-yl)ethoxy, 3-(pyrrolidin-1-yl)propoxy, 4-(pyrrolidin-1-yl)butoxy, (4-acetylpiperazin-1-yl)ethoxy, (1H-imidazol-1-yl)ethoxy, (4-methylpiperazin-1-yl)ethoxy, (piperidin-1-yl)ethoxy, (1-isopropylimidazolidine-2,4-dione)-3-ethoxy, (5-phenylimidazolidine-2,4-dione)-3-ethoxy, (imidazolidine-2,4-dione)-3-methyl, (2-azepan-1-yl)ethoxy, (2-azetidin-1-yl)ethoxy, N-(azetidin-3-yl)acetamide-1-ethoxy, (isoindoline-1,3-dione)-2-ethoxy, (5-oxopyrrolidin-2-yl)methoxy, (4-isopropylpiperazin-1-yl)methyl, N-isopropyl-N-(piperidin-4-methyl)acetamide-1-methyl, (4-(isopropylamino)piperidin-1-yl)methyl, (pyrrolidine-2,5-dione)ethoxy, and (1H-tetrazol-5-yl)methyl.

15 . The method according to claim 12 , wherein the compound of Formula III is selected from:

3-(3,5-dimethyl-4-(2-morpholinoethoxy)phenyl)-6,8-dimethoxyisoquinolin-1(2H)-one;

2-(3,5-dimethyl-4-(2-morpholinoethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

3-(3,5-dimethyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6,8-dimethoxyisoquinolin-1(2H)-one;

2-(3,5-dimethyl-4-(2-morpholinoethoxy)phenyl)quinazolin-4(3H)-one;

7-(3,5-dimethyl-4-(2-morpholinoethoxy)phenyl)-2,4-dimethoxy-1,6-naphthyridin-5(6H)-one;

5,7-dimethoxy-2-(4-((4-methylpiperazin-1-yl)methyl)phenyl)quinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(morpholinomethyl)phenyl)quinazolin-4(3H)-one;

2-(4-((4-ethylpiperazin-1-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

4-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)-N,N-dimethylpiperidine-1-carboxamide;

2-(4-(1-acetylpiperidin-4-yloxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(2-(isoindolin-2-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5-methoxyquinazolin-4(3H)-one;

5,7-dichloro-2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;

2-(4-(2-(4-acetylpiperazin-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(2-(1H-imidazol-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-7-methoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(piperidin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(3-methyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;

3-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)-1-isopropylimidazolidine-2,4-dione;

2-(3,5-dimethyl-4-(3-(pyrrolidin-1-yl)propoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(3-(pyrrolidin-1-yl)propyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(4-(pyrrolidin-1-yl)butoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

3-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)-5-phenylimidazolidine-2,4-dione;

3-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)benzyl)imidazolidine-2,4-dione;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethoxypyrido[2,3-d]pyrimidin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-7-fluoro-5-(pyrrolidin-1-yl)quinazolin-4(3H)-one;

5-chloro-2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;

2-(4-(2-(azepan-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-difluoroquinazolin-4(3H)-one;

2-(4-(2-(azetidin-1-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

N-(1-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)azetidin-3-yl)acetamide;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-diisopropoxyquinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethylquinazolin-4(3H)-one;

2-(2-(4-(6,8-dimethoxy-1-oxo-1,2-dihydroisoquinolin-3-yl)-2,6-dimethylphenoxy)ethyl)isoindoline-1,3-dione;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-diisopropoxypyrido[2,3-d]pyrimidin-4(3H)-one;

2-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)isoindoline-1,3-dione;

(S)-2-(3,5-dimethyl-4-((5-oxopyrrolidin-2-yl)methoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-((4-isopropylpiperazin-1-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

N-(1-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)benzyl)piperidin-4-yl)-N-isopropylacetamide;

2-(4-(2-(1-acetylazetidin-3-yl)ethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-((4-(isopropylamino)piperidin-1-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-((1H-tetrazol-5-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

and stereoisomers, tautomers, pharmaceutically acceptable salts, and hydrates thereof.

16 . A method of inhibiting BET proteins comprising administering a therapeutically effective amount of at least one compound of Formula IV:

or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein:

Q 1 is selected from nitrogen and C—Ra 1 ;

Q 3 is selected from nitrogen and C—Ra 3 ;

V is selected from CH and nitrogen;

Ra 1 and Ra 3 are independently selected from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkenyl, C 1 -C 6 alkynyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, amino, amide, and heterocycle;

or wherein Ra 1 and Ra 2 and/or Ra 2 and Ra 3 are connected to form a cycloalkyl or a heterocycle; and

Rb 3 and Rb 5 are independently selected from hydrogen, methyl, ethyl, C 3 -C 6 cycloalkyl, O 1 —O 3 alkoxy, and amino;

provided that:

if Ra 3 is alkoxy, then Ra 1 is not hydrogen; and

if Rb 5 is hydrogen, then Rb 3 is not —CH 2 OH.

17 . The method according to claim 16 , wherein

V is nitrogen;

Rb 3 and Rb 5 are independently selected from C 1 -C 6 alkyl and hydrogen;

Ra 3 is selected from hydrogen and C 1 -C 6 alkoxy;

Ra 1 is selected from methyl, ethyl, methoxy, ethoxy, and propoxy.

18 . The method according to claim 16 , wherein

V is nitrogen;

Rb 3 and Rb 5 are independently selected from methyl and hydrogen;

Ra 1 is selected from methyl, ethyl, methoxy, ethoxy, and propoxy; and

Ra 3 is selected from hydrogen, benzyloxyethoxy, methoxy, methoxyethoxy, (pyrrolidin-1-yl)ethoxy, phenoxyethoxy, and isopropoxyethoxy.

19 . The method according to claim 16 , wherein the compound of Formula IV is selected from:

1-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)pyrrolidine-2,5-dione;

7-(2-(benzyloxy)ethoxy)-5-methoxy-2-(pyridin-4-yl)quinazolin-4(3H)-one;

2-(2,6-dimethylpyridin-4-yl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(2,6-dimethylpyridin-4-yl)-5-methoxy-7-(2-methoxyethoxy)quinazolin-4(3H)-one;

2-(2,6-dimethylpyridin-4-yl)-5,7-bis(2-methoxyethoxy)quinazolin-4(3H)-one;

2-(2,6-dimethylpyridin-4-yl)-7-methoxy-5-(2-(pyrrolidin-1-yl)ethoxy)quinazolin-4(3H)-one;

2-(2,6-dimethylpyridin-4-yl)-5-methoxy-7-(2-phenoxyethoxy)quinazolin-4(3H)-one;

2-(2,6-dimethylpyridin-4-yl)-7-methoxy-5-(2-phenoxyethoxy)quinazolin-4(3H)-one;

2-(2,6-dimethylpyridin-4-yl)-7-methoxy-5-(2-methoxyethoxy)quinazolin-4(3H)-one;

2-(2,6-dimethylpyridin-4-yl)-5-methoxy-7-(2-(pyrrolidin-1-yl)ethoxy)quinazolin-4(3H)-one;

2-(2,6-dimethylpyridin-4-yl)-7-(2-isopropoxyethoxy)-5-methoxyquinazolin-4(3H)-one;

2-(2,6-dimethylpyridin-4-yl)-5,7-bis(2-isopropoxyethoxy)quinazolin-4(3H)-one;

7-(2-(benzyloxy)ethoxy)-2-(2,6-dimethylpyridin-4-yl)-5-methoxyquinazolin-4(3H)-one;

5-methoxy-7-(2-methoxyethoxy)-2-(2-methylpyridin-4-yl)quinazolin-4(3H)-one;

2-(2,6-dimethylpyridin-4-yl)-5-(2-isopropoxyethoxy)-7-methoxyquinazolin-4(3H)-one;

2-(2,6-dimethylpyridin-4-yl)-7-(2-methoxyethoxy)-5-(2-(pyrrolidin-1-yl)ethoxy)quinazolin-4(3H)-one;

and stereoisomers, tautomers, pharmaceutically acceptable salts, and hydrates thereof.

20 . A method of inhibiting BET proteins comprising administering a therapeutically effective amount of at least one compound of Formula V:

or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein:

Q is selected from CH and nitrogen;

Y is selected from oxygen, nitrogen, sulfur, NR 6 , CR 6 R 7 ;

A is C 1 -C 4 alkyl, wherein the alkyl chain may be connected to Y, D, and/or Rb 3 to form a cycloalkyl or heterocycle;

D, if present, is selected from —OR 1 , —NR 1 R 2 ;

R 1 and R 2 are independently selected from hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, sulfonamide, carboxamide, acyl, and nitrile, wherein R 1 and R 2 may be connected to form a cycloalkyl or a heterocycle;

R 6 and R 7 are independently selected from hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 alkoxy, hydroxyl, and halogen;

Ra 1 and Ra 3 are independently selected from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, halogen, amino, amide, hydroxyl, and heterocycle; and

Rb 3 is selected from hydrogen, halogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 alkoxy, hydroxyl, and amino;

provided that at least one of Ra 1 and Ra 3 is not hydrogen.

21 . The method according to claim 20 , wherein:

Ra 1 is selected from methyl, ethyl, methoxy, ethoxy, and propoxy;

Ra 3 is selected from hydrogen and C 1 -C 6 alkoxy;

Q is CH;

Rb 3 is selected from hydrogen, C 1 -C 6 alkyl, and C 1 -C 6 alkoxy;

Y is selected from oxygen;

A is C 1 -C 4 alkyl;

D, if present, is selected from hydroxy, heterocycle, and NR 1 R 2 ; and

R 1 and R 2 are independently selected from hydrogen and C 1 -C 6 alkyl, or alternatively, R 1 and R 2 are connected to form a cycloalkyl or a heterocycle.

22 . The method according to claim 20 , wherein:

Ra 1 is selected from methyl, ethyl, methoxy, ethoxy, and propoxy;

Ra 3 is selected from hydrogen and C 1 -C 6 alkoxy;

Q is CH;

Rb 3 is selected from hydrogen, methyl, and methoxy;

Y is oxygen;

A is selected from methyl and ethyl;

D, if present, is selected from hydroxy, pyrrolidin-1-yl, and NR 1 R 2 ; and

R 1 and R 2 are independently selected from hydrogen and acetyl, or alternatively, R 1 and R 2 are connected to form a cycloalkyl or a heterocycle.

23 . The method according to claim 20 , wherein the compound of Formula V is selected from:

2-(3,5-dimethoxyphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3-(2-hydroxyethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3-(2-hydroxyethoxy)-5-methylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(3-methoxy-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)quinazolin-4(3H)-one;

N-(2-(3-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-5-methoxyphenoxy)ethyl)acetamide;

5,7-dimethoxy-2-(3-methoxyphenyl)quinazolin-4(3H)-one;

and stereoisomers, tautomers, pharmaceutically acceptable salts, and hydrates thereof.

24 . The method according to claim 1 , wherein the therapeutically effective amount of the compound is administered with at least one pharmaceutically acceptable carrier in a pharmaceutically acceptable composition.

25 . The method according to claim 1 , wherein the compound of Formula I is administered to treat or prevent a cancer selected from cancers that exhibit c-myc overexpression, cancers that overexpress n-myc, cancers that that rely on the recruitment of p-TEFb to regulate activated oncogenes, Burkitt's lymphoma, acute myelogenous leukemia, multiple myeloma, aggressive human medulloblastoma, hematological, epithelial cancers, lung cancers, breast cancers, colon carcinomas, midline carcinomas, mesenchymal tumors, hepatic tumors, renal tumors, and neurological tumors.

26 . The method of claim 25 , wherein the compound of Formula I is administered in combination with another anti-cancer agent selected from the group consisting of bortezomib, thalidomide, dexamethasone, 5-azacitidine, decitabine, vorinostat, cyclophosphamide, a PI3K or mTOR inhibitor, rapamycin or a rapamycin analog, a gamma secretase inhibitor, an AMPK inducer, metformin, phenformin, an ornithine decarboxylase inhibitor, and difluoromethylornithine.